The late summer burst of IPO activity continued as sequencing specialist Pacific Biosciences Inc. took aim at the public markets, hoping to raise $200 million ahead of a planned 2011 commercial launch for third-generation sequencer PacBio RS. (BioWorld Today) Read More
